J Korean Androl Soc.
1993 Jun;11(1):23-27.
Effect of terazosin in symptomatic benign prostatic hyperplasia
- Affiliations
-
- 1Department of Urology, Yonsei University College of Medicine, Seoul, Korea.
Abstract
- We investigate the effectiveness of terazosin in symptomatic benign prostatic hyperplasia (BPH) in 31 evaluable patients. After 2 weeks of treatment, the initial dosage of 2 mg/day was elevated to 4mg/day in 17 randomly chosen patients. At 12 weeks' follow-up, 55% of the patients had > 30% improvement in their symptom scores, and 32% had a > 30% increase in their maximal flow rate. The maximal effect was achieved at 2 weeks, with no further improvement seen threafter in patients who had not already responded. There was no significant difference between the 2-mg and 4-mg doses. We concluded that terazosin is effective in some patients with infravesical obstruction secondary to BPH. Further studies are needed to evaluate the effect of increasing the dose in patients who do not respond to initial low-dose therapy.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Preliminary Results of Terazosin in the Treatment of Benign Prostatic Hypertrophy
- A 24 week Double-blind, Placebo-controlled Study using Terazosin in Treatment of Benign Prostatic Hyperplasia
- Effect of Tamsulosin, a Selective alpha1A-adrenoreceptor Antagonist, in Benign Prostatic Hyperplasia
- Clinical Experience of Symptomatic Management of BPH with Terazosin, Doxazosin or Combination of Terazosin and Finasteride
- Value of Prostate-Specific Antigen, Total Prostate Volume, Transition Zone Volume and Transition Zone Index as the Predictors of Effective Response for Alpha-blocker (Terazosin) Monotherapy in the Management of Benign Prostate Hyperplasia
